Recent insights on the impact of SWELL1 on metabolic syndromes
SWELL1 is a key component of the volume-regulated anion channel (VRAC) and participates in cell volume regulation as an ion channel plasma membrane protein. While early studies focused on its role in immune cell development and tumor progression, recent studies have revealed that SWELL1 plays an imp...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1552176/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850096751861563392 |
|---|---|
| author | Mianhong Qin Xuejie Yi Ziqiang Duan Bo Chang Tao Li |
| author_facet | Mianhong Qin Xuejie Yi Ziqiang Duan Bo Chang Tao Li |
| author_sort | Mianhong Qin |
| collection | DOAJ |
| description | SWELL1 is a key component of the volume-regulated anion channel (VRAC) and participates in cell volume regulation as an ion channel plasma membrane protein. While early studies focused on its role in immune cell development and tumor progression, recent studies have revealed that SWELL1 plays an important role in metabolic diseases. Studies have shown that SWELL1 is extensively involved in physiological processes in peripheral metabolic tissues, including adipocyte hypertrophy, skeletal muscle volume regulation, insulin secretion, and hepatic lipid metabolism through interactions with the insulin signaling pathway. These functions play key roles in the pathogenesis of obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD), suggesting that SWELL1 may be a new target for the treatment of metabolic diseases. In this review, we focus on the structural and functional characteristics of SWELL1 to provide an in-depth explanation of its role in the development of metabolic syndrome, especially the regulation of the insulin signaling pathway, and provide a basis for the development of therapeutic strategies for metabolic diseases targeting SWELL1. |
| format | Article |
| id | doaj-art-7758caeb9c7440c3bb8eb4c973c396f0 |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-7758caeb9c7440c3bb8eb4c973c396f02025-08-20T02:41:10ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-03-011610.3389/fphar.2025.15521761552176Recent insights on the impact of SWELL1 on metabolic syndromesMianhong Qin0Xuejie Yi1Ziqiang Duan2Bo Chang3Tao Li4School of Sports Health, Shenyang Sport University, Shenyang, Liaoning, ChinaSchool of Sports Health, Shenyang Sport University, Shenyang, Liaoning, ChinaSchool of Sports Health, Shenyang Sport University, Shenyang, Liaoning, ChinaCollege of Sport Science, Zhuhai College of Science and Technology, Zhuhai, Guangdong, ChinaSchool of Sports Health, Shenyang Sport University, Shenyang, Liaoning, ChinaSWELL1 is a key component of the volume-regulated anion channel (VRAC) and participates in cell volume regulation as an ion channel plasma membrane protein. While early studies focused on its role in immune cell development and tumor progression, recent studies have revealed that SWELL1 plays an important role in metabolic diseases. Studies have shown that SWELL1 is extensively involved in physiological processes in peripheral metabolic tissues, including adipocyte hypertrophy, skeletal muscle volume regulation, insulin secretion, and hepatic lipid metabolism through interactions with the insulin signaling pathway. These functions play key roles in the pathogenesis of obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD), suggesting that SWELL1 may be a new target for the treatment of metabolic diseases. In this review, we focus on the structural and functional characteristics of SWELL1 to provide an in-depth explanation of its role in the development of metabolic syndrome, especially the regulation of the insulin signaling pathway, and provide a basis for the development of therapeutic strategies for metabolic diseases targeting SWELL1.https://www.frontiersin.org/articles/10.3389/fphar.2025.1552176/fullSWELL1volume-regulated anion channelmetabolic syndromeglucose metabolismlipid metabolism |
| spellingShingle | Mianhong Qin Xuejie Yi Ziqiang Duan Bo Chang Tao Li Recent insights on the impact of SWELL1 on metabolic syndromes Frontiers in Pharmacology SWELL1 volume-regulated anion channel metabolic syndrome glucose metabolism lipid metabolism |
| title | Recent insights on the impact of SWELL1 on metabolic syndromes |
| title_full | Recent insights on the impact of SWELL1 on metabolic syndromes |
| title_fullStr | Recent insights on the impact of SWELL1 on metabolic syndromes |
| title_full_unstemmed | Recent insights on the impact of SWELL1 on metabolic syndromes |
| title_short | Recent insights on the impact of SWELL1 on metabolic syndromes |
| title_sort | recent insights on the impact of swell1 on metabolic syndromes |
| topic | SWELL1 volume-regulated anion channel metabolic syndrome glucose metabolism lipid metabolism |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1552176/full |
| work_keys_str_mv | AT mianhongqin recentinsightsontheimpactofswell1onmetabolicsyndromes AT xuejieyi recentinsightsontheimpactofswell1onmetabolicsyndromes AT ziqiangduan recentinsightsontheimpactofswell1onmetabolicsyndromes AT bochang recentinsightsontheimpactofswell1onmetabolicsyndromes AT taoli recentinsightsontheimpactofswell1onmetabolicsyndromes |